MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

Amgen is developing monthly GLP-1 injections aimed at improving convenience and long-term adherence for patients.

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not ...

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All Amgen (NASDAQ:AMGN) executives used a Jefferies investor ...

At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Amgen’s Executive Vice ...

Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while promising — are still being evaluated by industry stakeholders. The pharma giant ...

In the persistence and adherence analysis, which looked at 28 studies including 267,542 patients, Amgen found that 69% of ...

Add Yahoo as a preferred source to see more of our stories on Google. In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. Also Read: Jim Cramer Says Eli ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial. The company announced Monday that it has ...